Compass Therapeutics, Inc. (CMPX) disclosed it received a deficiency letter from Nasdaq on November 19, 2026, for failing to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. The company has been granted a 180-day compliance period to resolve the issue. There is no immediate effect on the company's stock listing, which will continue to trade on The Nasdaq Capital Market.
Key Details
- Non-Compliance Event: The company's common stock closed below the $1.00 minimum bid price required by Nasdaq Listing Rule 5550(a)(2) for 30 consecutive business days.
- Compliance Period: CMPX has until May 18, 2027, to regain compliance. To do so, the stock's closing bid price must be at or above $1.00 for a minimum of 10 consecutive business days.
- Potential Actions: The company intends to monitor its stock price and may consider available options, including a reverse stock split, to regain compliance. A second 180-day compliance period may be granted if certain conditions are met.